Vectura have announced the signing of a global licence and development agreement with Aerami Therapeutics Inc. for inhaled imatinib (VR325) for the treatment of Pulmonary Arterial Hypertension. Aerami will be responsible for the overall development and commercialisation of inhaled imatinib, with Vectura providing development services expertise and a license to its FOX® mesh nebuliser technology. Under the partnership, Vectura will receive development fees, revenue from the provision of FOX® nebuliser devices and mid-single digit royalties from global net sales of imatinib, together with regulatory and success-related milestone payments. There is no upfront payment. Please click here for the full update.